Research Topics
| H H FeldmanSummaryAffiliation: University of British Columbia Country: Canada Publications
| Collaborators
|
Detail Information
Publications
Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease and the effect on caregiver burdenHoward Feldman
Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
J Am Geriatr Soc 51:737-44. 2003....
Familial frontotemporal dementia with neuronal intranuclear inclusions is not a polyglutamine expansion diseaseIan R Mackenzie
Department of Pathology, University of British Columbia, Vancouver, BC, Canada
BMC Neurol 6:32. 2006..The genetic basis of familial FTLD-U is currently not known, however the presence of NII suggests that a subset of cases may represent a polyglutamine expansion disease...- Predicting response to acetylcholinesterase inhibitor treatment in Alzheimer disease: has the time come?Howard H Feldman
Division of Neurology, University of British Columbia Hospital, Vancouver, BC, Canada
Nat Clin Pract Neurol 5:128-9. 2009..We remind clinicians that small improvements in cognition matter most when a concurrent measurable benefit is seen in daily function... - Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx studyHoward H Feldman
Division of Neurology, University of British Columbia Hospital, Vancouver, Canada
Lancet Neurol 6:501-12. 2007..To assess the effect of rivastigmine in patients with mild cognitive impairment (MCI) on the time to clinical diagnosis of Alzheimer's disease (AD) and the rate of cognitive decline... - Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatmentHoward H Feldman
Division of Neurology, University of British Columbia, Vancouver, BC, Canada
Alzheimer Dis Assoc Disord 20:263-8. 2006..These post hoc analyses in moderate-to-severe AD patients receiving stable donepezil treatment suggest that memantine may impact overall functional levels, and some of the cognitive processing underlying ADL performance... 
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's diseaseHoward H Feldman
Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, British Columbia, Canada
J Neurol Neurosurg Psychiatry 78:1056-63. 2007..To evaluate the efficacy and safety of rapidly titrated rivastigmine administered twice (BID) or three times (TID) daily in patients with mild to moderate Alzheimer's disease (AD)...
Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADeH H Feldman
Division of Neurology, University of British Columbia, UBCH Clinic for Alzheimer s Disease and Related Disorders, Vancouver, Canada
Neurology 74:956-64. 2010..The LEADe study is a randomized controlled trial (RCT) evaluating the efficacy and safety of atorvastatin in patients with mild to moderate AD...- Diagnosis and treatment of dementia: 2. DiagnosisHoward H Feldman
Division of Neurology, Department of Medicine, University of British Columbia, and the University of British Columbia Hospital Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC
CMAJ 178:825-36. 2008..In this article, we provide physicians with practical guidance on the diagnosis of dementia based on recommendations from the Third Canadian Consensus Conference on the Diagnosis and Treatment of Dementia, held in March 2006... - Analyses of mortality risk in patients with dementia treated with galantamineH H Feldman
University British Columbia Hospital, Vancouver, Canada
Acta Neurol Scand 119:22-31. 2009..To analyze mortality data from patients with Alzheimer's disease (AD), Alzheimer's plus cerebrovascular disease (AD + CVD) or vascular dementia (VaD)... - Treatment with galantamine and time to nursing home placement in Alzheimer's disease patients with and without cerebrovascular diseaseHoward H Feldman
Division of Neurology, University British Columbia, Vancouver, British Columbia, Canada
Int J Geriatr Psychiatry 24:479-88. 2009.... - Mild cognitive impairmentHoward H Feldman
Division of Neurology, Dept of Medicine, Clinic for Alzheimer Disease and Related Disorders, University of British Columbia, S192 2211 Wesbrook Mall, Vancouver, British Columbia, Canada V6T 2B5
Am J Geriatr Psychiatry 13:645-55. 2005..The essentials of management include a thorough assessment directed at etiological determination and counseling and judicious use of available therapeutics... - Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trialHoward Feldman
Division of Neurology, University of British Columbia, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
Int J Geriatr Psychiatry 20:559-69. 2005..Additional analyses examined whether donepezil's treatment effects were consistent across the full range of baseline AD severity studied (sMMSE score 5-17)... - Economic evaluation of donepezil in moderate to severe Alzheimer diseaseH Feldman
Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
Neurology 63:644-50. 2004..To investigate the costs to society of Alzheimer disease (AD) care in a multinational, randomized, placebo-controlled trial of donepezil in patients with moderate to severe AD... - Behavioral symptoms in mild cognitive impairmentH Feldman
Division of Neurology, University of British Columbia, Vancouver Hospital and Health Sciences Center, Vancouver, British Columbia, Canada
Neurology 62:1199-201. 2004..NPI+ subjects had significantly greater impairment on global, cognitive, and functional scores than NPI- subjects. The presence of neuropsychiatric symptoms appears to be a marker of MCI severity... - A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline resultsH Feldman
Department of Medicine Neurology, Vancouver Hospital and Health Sciences Center, University of British Columbia, S192 2211 Wesbrook Mall, Vancouver, British Columbia V6T 2B5, Canada
Neuroepidemiology 22:265-74. 2003..4%, dementia with Lewy bodies 2.5%, and unclassifiable 1.8%. The ACCORD cohort will allow a detailed study of the longitudinal course of CIND, and the longer-term outcomes of both treated and untreated dementia subjects... - Cognition, function, and caregiving time patterns in patients with mild-to-moderate Alzheimer disease: a 12-month analysisHoward H Feldman
Division of Neurology and Clinic for Alzheimer s Disease and Related Disorders, University of British Columbia, Vancouver, BC, Canada
Alzheimer Dis Assoc Disord 19:29-36. 2005..Small changes in ADAS-cog are nevertheless associated with a substantial measurable effect on the daily lives of both patients and caregivers... - A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's diseaseH Feldman
Division of Neurology, UBC Hospital, Clinic for Alzheimer s Disease and Related Disorders, Vancouver, BC, Canada
Neurology 57:613-20. 2001..To investigate the efficacy and safety of donepezil in patients with moderate to severe AD (standardized Mini-Mental State Examination [sMMSE] scores of 5 to 17; Functional Assessment Staging score < or =6 at baseline)... - Neuropsychological subgroups of cognitively-impaired-not-demented (CIND) individuals: delineation, reliability, and predictive validityKevin R Peters
Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada
J Clin Exp Neuropsychol 27:164-88. 2005..The Verbal Dysfunction subgroup was most likely to show improvement in cognitive status. The cognitive heterogeneity of the CIND condition must be taken into account in future research focusing on the early identification of dementia... - Neuropsychological characterization of cognitively-impaired-not-demented (CIND) individuals: clinical comparison dataKevin R Peters
University of British Columbia, Vancouver, BC, Canada
Clin Neuropsychol 18:208-28. 2004..The results support the impression that CIND is a cognitively heterogeneous condition... - Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and AgingGing Yuek R Hsiung
Department of Medicine, Clinic for Alzheimer s Disease and Related Disorders, University of British Columbia, Vancouver, BC
CMAJ 171:863-7. 2004..However, its effect on predicting conversion from normal to "cognitive impairment, no dementia" (CIND) and from CIND to AD is less clear... - Extrapyramidal features in patients with motor neuron disease and dementia; a clinicopathological correlative studyIan R Mackenzie
Department of Pathology, Vancouver General Hospital and University of British Columbia, 855 West 12th Avenue, V5Z 1M9, Vancouver, British Columbia, Canada
Acta Neuropathol 107:336-40. 2004..This study illustrates the utility of ubiquitin immunohistochemistry in demonstrating the range of pathology in MND and provides a neuropathological correlate for the extrapyramidal features which may occur in MND with dementia... - Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer diseaseHao Li
GlaxoSmithKline, Research Triangle Park, North Carolina, USA
Arch Neurol 65:45-53. 2008..To identify single-nucleotide polymorphisms (SNPs) associated with risk and age at onset of Alzheimer disease (AD) in a genomewide association study of 469 438 SNPs... - Clinical presentation of prodromal frontotemporal dementiaBradley J Hallam
Division of Neurology, Geriatric Psychiatry Outreach Team, Vancouver Hospital, Vancouver, British Columbia
Am J Alzheimers Dis Other Demen 22:456-67. 2007.... - Synergistic effect of apolipoprotein E epsilon4 and butyrylcholinesterase K-variant on progression from mild cognitive impairment to Alzheimer's diseaseRoger Lane
Novartis Pharmaceuticals Corporation, East Hanover, New Jersey 07936 1080, USA
Pharmacogenet Genomics 18:289-98. 2008..To evaluate the synergistic effects of the apolipoprotein E (APOE) epsilon4 and butyrylcholinesterase K-variant (BCHE-K) alleles on progression to Alzheimer's disease (AD) in individuals with mild cognitive impairment (MCI)... - Assessing mental status in dementia: the behavioral neurology assessment--right time? Right place?Howard H Feldman
Can J Neurol Sci 32:138-9. 2005 - Transition from cognitively impaired not demented to Alzheimer's disease: an analysis of changes in functional abilities in a dementia clinic cohortGing Yuek R Hsiung
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Dement Geriatr Cogn Disord 25:483-90. 2008..We evaluated whether impairments on the Disability Assessment for Dementia (DAD) and Functional Rating Scale (FRS) can predict progression to AD... - Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individualsKevin R Peters
Department of Psychology, Trent University, Peterborough, Ontario, Canada
Am J Geriatr Psychiatry 16:136-44. 2008.... - Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteriaBruno Dubois
INSERM U610, Hopital de la Salpetriere, Paris, France
Lancet Neurol 6:734-46. 2007..Validation studies in existing and prospective cohorts are needed to advance these criteria and optimise their sensitivity, specificity, and accuracy... - Outcomes of cognitively impaired not demented at 2 years in the Canadian Cohort Study of Cognitive Impairment and Related DementiasGing-Yuek R Hsiung
Division of Neurology, Department of Medicine University of British Columbia, Vancouver, Canada
Dement Geriatr Cogn Disord 22:413-20. 2006..CONCLUSION: CIND consists of a heterogeneous group of disorders that can be classified syndromically. Many subclassess - not just those with pre-AD CIND - are at high risk of progression to dementia, usually to Alzheimer's disease... - Cognitive impairment no dementia - neuropsychological and neuroimaging characterization of an amnestic subgroupClaudia Jacova
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Dement Geriatr Cogn Disord 25:238-47. 2008..In this study a prospectively defined amnestic CIND group was characterized on a detailed neuropsychological test battery and on structural magnetic resonance imaging (MRI) measures... - Dropouts and refusals in observational studies: lessons for prevention trialsClaudia Jacova
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Neurology 67:S17-20. 2006..Targeted strategies to retain these individuals within prevention studies will be needed to achieve sufficient study power and validity... - Primary prevention and delay of onset of AD/dementiaHoward H Feldman
Division of Neurology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada
Can J Neurol Sci 34:S84-9. 2007..It is foreseeable that regulatory authorities will be presented with primary prevention RCTs for approval and labelling, and that criteria to evaluate such evidence still need to be developed... - Is mild cognitive impairment a valid target of therapyKenneth Rockwood
Department of Medicine Geriatric Medicine and Neurology, Dalhousie University, Halifax, NS, Canada
Can J Neurol Sci 34:S90-6. 2007..The phenomenon of slowing or non-progression itself should be investigated, and such investigations likely should extend to people now classified as having mild dementia... - Progress in clinical neurosciences: Canadian guidelines for the development of antidementia therapies: a conceptual summaryHoward H Feldman
Division of Neurology, University of British Columbia, Clinic for Alzheimer's Disease and Related Disorders, Vancouver, BC, Canada
Can J Neurol Sci 33:6-26. 2006..They are intended to provide a common point of reference and guidance in Canada for therapeutic development of the dementias... - Clinical phenotypes of Cerebral Amyloid AngiopathyLuis F Maia
Department of Neurology, Hospital Geral Santo Antonio, Porto, Portugal
J Neurol Sci 257:23-30. 2007..Dementia, cognitive impairment and transient neurological symptoms or signs are also being increasingly recognized as part of the CAA clinical spectrum. This review covers the clinical, pathological and neuroimaging aspects of CAA... - Ubiquitin immunohistochemistry suggests classic motor neuron disease, motor neuron disease with dementia, and frontotemporal dementia of the motor neuron disease type represent a clinicopathologic spectrumIan R A Mackenzie
Division of Neuropathology, University of British Columbia, Vancouver, Canada
J Neuropathol Exp Neurol 64:730-9. 2005..The only finding restricted to a specific subgroup of patients was the presence of ub-ir neuronal intranuclear inclusions in some cases of familial FTD... - Cholesterol in Alzheimer's diseaseLeila A Shobab
Division of Neurology, Department of Medicine, Clinic for Alzheimer Disease and Related Disorders, Vancouver Costal Health, University of British Columbia, Vancouver BC, V6T 2B5, Canada
Lancet Neurol 4:841-52. 2005..In this review, we summarise current knowledge of the role of cholesterol metabolism in the pathogenesis of AD and examine the potential of statins in the prevention and treatment of AD... - Superficial siderosis: a potential diagnostic marker of cerebral amyloid angiopathy in Alzheimer diseaseHoward H Feldman
Stroke 39:2894-7. 2008..Two had neuropathological examination confirming superficial siderosis, AD, and CAA. CONCLUSIONS: Superficial siderosis should be recognized within the spectrum of AD with CAA and considered as a possible antemortem diagnostic feature... - Early identification of Alzheimer's disease: what have we learned from mild cognitive impairment?Howard H Feldman
CNS Spectr 13:4-7. 2008 - The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin geneIan R A Mackenzie
Department of Pathology and Laboratory Medicine, University of British Columbia and Vancouver Coastal Health Vancouver, BC, Canada
Brain 129:3081-90. 2006..These findings suggest that FTD caused by PGRN mutations has a recognizable pathology with the most characteristic feature being ub-ir NII... - Potential for misclassification of mild cognitive impairment: a study of memory scores on the Wechsler Memory Scale-III in healthy older adultsBrian L Brooks
British Columbia Mental Health and Addiction Services, Riverview Hospital, Coquitlam, British Columbia
J Int Neuropsychol Soc 14:463-78. 2008..Understanding the base rates of low scores can reduce the overinterpretation of low memory scores and minimize false-positive misclassification...